Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN – Get Free Report) saw a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 35,200 shares, a drop of 46.8% from the October 31st total of 66,200 shares. Based on an average trading volume of 441,700 shares, the days-to-cover ratio is currently 0.1 days. Currently, 4.4% of the shares of the company are sold short.
Wall Street Analysts Forecast Growth
Separately, Chardan Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of Sonnet BioTherapeutics in a research report on Friday, August 23rd.
Read Our Latest Report on SONN
Hedge Funds Weigh In On Sonnet BioTherapeutics
Sonnet BioTherapeutics Stock Performance
Shares of SONN traded down $0.06 on Friday, reaching $2.57. 30,658 shares of the company’s stock traded hands, compared to its average volume of 133,315. The stock’s 50 day simple moving average is $3.99 and its two-hundred day simple moving average is $2.09. Sonnet BioTherapeutics has a 52-week low of $2.50 and a 52-week high of $18.72.
About Sonnet BioTherapeutics
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Featured Stories
- Five stocks we like better than Sonnet BioTherapeutics
- Canada Bond Market Holiday: How to Invest and Trade
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- Why is the Ex-Dividend Date Significant to Investors?
- MarketBeat Week in Review – 11/25 – 11/29
- What Does a Stock Split Mean?
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.